Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Analysis summary4-Traders Strategies

Jordan Dufee

 
 
share with twitter share with LinkedIn share with facebook
share via e-mail

After the accumulation, an upward acceleration ?

Strategy published on 10/06/2017 | 09:34
long trade
Live
Entry price : 60.47€ | Target : 66€ | Stop-loss : 58€ | Potential : 9.15%
From a horizontal accumulation phase, the timing seems good to buy shares in UCB and to get ahead of a break-out on the upside of the congestion area.
Investors have an opportunity to buy the stock and target the € 66.
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • In a short-term perspective, the company has interesting fundamentals.

Strengths
  • The share is getting closer to its long-term support in weekly data, at EUR 56.5, which offers good timing for buyers.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • The company is in a robust financial situation considering its net cash and margin position.

Weaknesses
  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
Ratings chart
Subsector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
UCB-1.08%13 852
JOHNSON & JOHNSON18.42%366 178
NOVARTIS13.23%225 160
ROCHE HOLDING LTD.5.20%216 764
PFIZER11.88%216 409
MERCK AND COMPANY7.68%172 887
AMGEN25.17%133 538
SANOFI8.71%124 781
BAYER19.19%115 485
BRISTOL-MYERS SQUIBB COMPAN..11.72%107 071
CELGENE CORPORATION17.89%106 760
Autres valeurs du secteur
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (€)
Sales 2017 4 339 M
EBIT 2017 964 M
Net income 2017 614 M
Debt 2017 579 M
Yield 2017 1,99%
P/E ratio 2017 17,71
P/E ratio 2018 15,24
EV / Sales 2017 2,83x
EV / Sales 2018 2,61x
Capitalization 11 719 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart UCB
Duration : Period : Day
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Duration : Period : Week
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders